Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study is to evaluate the efficacy and safety of an antifibrotic agent, pirfenidone as treatment of systemic sclerosis. The primary outcome of this study is improvement of skin fibrosis.
Epistemonikos ID: ca24825bff2fc500e8e894008e1ccba51dcb6507
First added on: May 20, 2024